Pfizer (NYSE:PFE) recently received a CDC recommendation for wider use of its RSV vaccine, ABRYSVO, in adults aged 50-59 at ...

Pfizer's strong R&D pipeline, 7.5%+ dividend yield, & undervalued PE ratio make PFE stock a compelling investment opportunity ...

CDC panel expands RSV vaccine recommendations for at-risk adults aged 50-59, including Pfizer's Abrysvo. Read more here.

Novavax (NVAX) announced preliminary results from the SHIELD-Utah study that showed Novavax’s COVID-19 Vaccine, Adjuvanted 2024-2025 Formula ...

Pfizer (PFE) announced that the U.S. Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted to expand ...

The CDC's vaccine committee will convene for a two-day meeting this week to consider recommendations on vaccines, including the COVID-19 vaccine for 2025-2026.

Here is why it could be a smart buy now. Not every stock needs to be a millionaire-maker. Sometimes, slow and steady can win ...

The CDC's Advisory Committee on Immunization Practices (ACIP) voted 14-0, with one abstention, on Wednesday to recommend that ...

Danuglipron: According to the company's latest statement, one patient experienced a potential liver injury that may have been ...

ATLANTA (AP) — A key vaccine advisory committee met for the first time under new U.S. Health Secretary Robert F. Kennedy Jr., ...